This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2024 Zacks Investment Research | 10 S Riverside Plaza Suite #1600 | Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +24.03% per year. These returns cover a period from January 1, 1988 through July 1, 2024. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
5 Beaten-Down Medical Product Stocks to Rebound in 2019
by Nabaparna Bhattacharya
As the Medical product industry is witnessing temporary sluggishness, a sneak peek into some possible outperformers in 2019 could be a great idea for investors.
Chimerix (CMRX) Reports Q3 Loss, Misses Revenue Estimates
by Zacks Equity Research
Chimerix (CMRX) delivered earnings and revenue surprises of 21.43% and -61.84%, respectively, for the quarter ended September 2018. Do the numbers hold clues to what lies ahead for the stock?
Chimerix (CMRX) Reports Q2 Loss, Tops Revenue Estimates
by Zacks Equity Research
Chimerix (CMRX) delivered earnings and revenue surprises of 11.36% and 27.32%, respectively, for the quarter ended June 2018. Do the numbers hold clues to what lies ahead for the stock?
Chimerix Q4 Loss Narrower Than Expected, Revenues Exceed
by Zacks Equity Research
Chimerix (CMRX) makes progress in Q4 through advancement with lead product candidate, brincidofovir. Revenues decline from lower reimbursable expenses regarding BARDA developmental contract.
Chimerix (CMRX) Q2 Loss Narrower than Expected, Revenues Down
by Zacks Equity Research
Chimerix (CMRX) revenues in Q2 were hurt by reduced reimbursable expenses related to the company's BARDA developmental contract.
Medical Device Stocks to Beat Estimates this Earnings Season
by Zacks Equity Research
Most of the MedTech majors will be releasing earnings later this month.
Universal Health (UHS) Q4 Earnings: What's in the Cards?
by Zacks Equity Research
Universal Health Services, Inc. (UHS) will release fourth-quarter 2016 results on Feb 28, after the market closes. Last quarter, the company posted a negative earnings surprise of 4.19%.
5 Breakout Stocks for Superior Returns
by Swarup Gupta
If properly implemented, such a strategy could deliver impressive returns.
Will Chimerix (CMRX) Continue to Surge Higher?
by Zacks Equity Research
As of late, it has definitely been a great time to be an investor in Chimerix, Inc. (CMRX)
Falling Earnings Estimates Signal Weakness Ahead for Agios Pharmaceuticals (AGIO)
by Zacks Equity Research
Agios Pharmaceuticals (AGIO) is one stock you should avoid as it has seen a significant price decline and negative earnings estimate revisions.